A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metsastatic breast cancer

Trial Profile

A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metsastatic breast cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms CONCEPT
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, 38 patients have been recuited to date.
    • 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, if interim analysis of this study does not show futility then the study will proceed to phase III study of 160 patients.
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top